The Lynx Group
Cholangiocarcinoma News

Role of Intraductal Treatment and Endoscopic Oncologists in the Management of Unresectable Extrahepatic Cholangiocarcinoma

September/October 2021, Vol 2, No 3

Although cholangiocarcinoma (CCA) is a rare cancer that originates in the bile ducts, its incidence rate continues to rise in the United States, and many patients are diagnosed late, with unresectable tumor and poor prognosis. The majority of patients with extrahepatic CCA, including the perihilar subtype, require referral to a center with expertise in endoscopic retrograde cholangiopancreatography (ERCP) and interventional radiology, because of the complexities in obtaining a definitive diagnosis and durable biliary drainage.

In a recent editorial, Srinivas Gaddam, MD, MPH, Assistant Professor of Medicine, Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, and Gregory A. Coté, MD, MS, Associate Professor, Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of South Carolina, Charleston, reviewed the role of intraductal therapies and the importance of integrating the endoscopic oncologist into the treatment plan for patients with nonresectable CCA.

Because successful and sustained “biliary drainage is associated with prolonging life and is required for the administration of systemic chemotherapy, it follows that the interventional endoscopist may be considered an ‘endoscopic oncologist’ in the treatment of patients with extrahepatic CCA,” explained Dr Gaddam and Dr Coté.

Once cholestasis has been palliated, maintaining endobiliary stent patency is another challenge. Intraductal interventions, such as radiofrequency ablation and photodynamic therapy, may extend the durability of endobiliary stents. Initial clinical trials of photodynamic therapy showed improved survival, but later studies raised concerns regarding photodynamic therapy–specific issues, including photosensitivity-related burns and secondary bile duct strictures.

Radiofrequency ablation, by contrast, is easier to implement than photodynamic therapy during ERCP. No administration of light-sensitizing chemicals is required, and the catheter technology is simpler and more durable. Intraductal radiofrequency ablation has not been shown to extend life; however, the most likely mechanism for radiofrequency ablation to prolong survival in patients with CCA is its impact on maintaining biliary drainage.

Dr Gaddam and Dr Coté also discussed where radiofrequency ablation should fall in the treatment algorithm. They suggested that given the reduced risk and cost of this treatment, and the low probability that it will have a negative impact on biliary drainage, endoscopists should be comfortable with this procedure and consider its use in patients with unresectable extrahepatic CCA who have a good performance status (ie, survival of 6 months or longer).

“Given the complexity of the disease biology, heterogeneity in biliary obstruction at presentation, and variability in baseline performance status/ability to tolerate systemic therapies, randomized trials of endoscopic interventions for unresectable extrahepatic cholangiocarcinoma must be designed with input from medical and surgical oncologists, radiologists, and interventional radiologists,” Dr Gaddam and Dr Coté noted. “It’s time to move the field from plastic versus metal and pilot studies of intraductal ablation to a concerted effort to better integrate the endoscopic oncologist into a personalized approach to treatment.”

Source: Gaddam S, Coté GA. The importance of the “endoscopic oncologist” in the treatment of nonoperable cholangiocarcinoma. Gastrointest Endosc. 2020;92:1213-1215.

Related Items

FDA Grants TT-00420, a Multi-Kinase Inhibitor, Fast-Track Review for Cholangiocarcinoma
Web Exclusives
On November 3, 2021, TransThera Sciences announced that the FDA granted its investigational drug, TT-00420, a spectrum-selective multi-kinase inhibitor, a fast-track designation for the treatment of patients with cholangiocarcinoma (CCA) who have no available standard treatment options. In preclinical studies, TT-00420 has shown high activity in a variety of FGFR mutations.
Hot Topics in Cholangiocarcinoma and Biliary Tract Cancers: ASCO Highlights
September/October 2021, Vol 2, No 3
At the CCA Summit during the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), Mitesh J. Borad, MD, Associate Professor of Medicine, Mayo Clinic, Phoenix, AZ, reviewed some of the key topics presented at ASCO 2021 related to cholangiocarcinoma (CCA) and other biliary tract cancers. Before turning to the specific presentations, Dr Borad welcomed the May 28, 2021, FDA approval of infigratinib (Truseltiq) for patients with advanced or metastatic CCA and FGFR2 fusions or rearrangements. Infigratinib follows pemigatinib (Pemazyre) as the second targeted therapy now available for this patient population.
Important Role of Screening for Genomic Alterations in Cholangiocarcinoma
September/October 2021, Vol 2, No 3
Comprehensive molecular profiling has demonstrated a diverse landscape of oncogenic genomic alterations in cholangiocarcinoma (CCA), which are often the drivers of CCA. In a recent review article, Tanios S. Bekaii-Saab, MD, FACP, Vice Chair and Section Chief for Medical Oncology, Department of Internal Medicine, Mayo Clinic Cancer Center, Phoenix, AZ, and colleagues provided an overview of the molecular heterogeneity of CCA, discussing the role of molecular tests for the diagnosis of patients with intrahepatic CCA, and the implications of the genomic alterations in the treatment of patients with this aggressive disease.
Tibsovo First Targeted Therapy FDA Approved for Advanced or Metastatic CCA with IDH1 Mutation
September/October 2021, Vol 2, No 3
On August 25, 2021, the FDA approved ivosidenib (Tibsovo; Servier Pharmaceuticals), an oral IDH1 inhibitor, for the treatment of adults with previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) and an IDH1 mutation, as detected by an FDA-approved test. The FDA granted ivosidenib a priority review for this indication and an orphan drug designation.
National Survey Pinpoints Reasons Oncologists Do Not Order Molecular Testing
September/October 2021, Vol 2, No 3
Multimarker tumor panel testing is beneficial in helping to inform treatment choice in precision oncology. However, little is known about the clinic-based and organizational factors related to multimarker tumor panel testing, and why oncologists may not choose this testing.
Role of Radiology in Intrahepatic Cholangiocarcinoma Addressed at 2 Interventional Oncology and Radiology Meetings
September/October 2021, Vol 2, No 3
Key topics related to intrahepatic cholangiocarcinoma (CCA) were presented at the 2021 Society of Interventional Oncology (SIO) and the Society of Interventional Radiology (SIR) meetings and were discussed at the CCA Summit. Bruno C. Odisio, MD, FSIR, Interventional Radiologist and Co-Director of Research, Interventional Radiology, M.D. Anderson Cancer Center, Houston, TX, reviewed the findings.
Ivosidenib Approved for Advanced or Metastatic Cholangiocarcinoma
Web Exclusives
Ivosidenib has been approved by the FDA for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
Recent Developments in Genomic-Driven Therapies for Cholangiocarcinoma
June/July 2021, Vol 2, No 2
Personalized medicine has expanded the treatment options for patients with cholangiocarcinoma (CCA). At the 2021 Annual Meeting of the Cholangiocarcinoma Foundation (CCF), Ghassan K. Abou-Alfa, MD, MBA, Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, discussed recent developments in personalized therapies, highlighting genomic alterations that are informing the new therapies for patients with CCA.
FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma
June/July 2021, Vol 2, No 2
The FDA granted accelerated approval to the kinase inhibitor infigratinib (Truseltiq) for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) that harbors an FGFR2 fusion or other rearrangement.
Futibatinib in Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements: Primary Results of FOENIX-CCA2 Presented at AACR 2021
June/July 2021, Vol 2, No 2
The primary results of the phase 2 FOENIX-CCA2 clinical trial of futibatinib in patients with previously treated intrahepatic cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements were presented by Lipika Goyal, MD, MPhil, Assistant Professor of Medicine, Massachusetts General Hospital, Boston, at the 2021 Annual Meeting of the American Association for Cancer Research (AACR).

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: